Xevinapant
- Generic Name
- Xevinapant
- Drug Type
- Small Molecule
- Chemical Formula
- C32H43N5O4
- CAS Number
- 1071992-99-8
- Unique Ingredient Identifier
- N65WC8PXDD
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 12
- Registration Number
- NCT06463184
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
- Conditions
- Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckHead and Neck Cancer
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 42
- Registration Number
- NCT06110195
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
- Conditions
- Oropharyngeal Squamous Cell CarcinomaStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaStage IV Laryngeal Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Chest RadiographyProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Registration Number
- NCT06084845
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 18
- Registration Number
- NCT06056310
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Montefiore Medical Center PRIME, Bronx, New York, United States
🇧🇪Universitair Ziekenhuis Gent - Medical Oncology, Gent, Belgium
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 19
- Registration Number
- NCT05930938
- Locations
- 🇫🇷
Hôpital Nord Franche Compté, Montbéliard, France
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 230
- Registration Number
- NCT05724602
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇸🇮The Institute Of Oncology, Ljubljana, Slovenia
🇳🇴Helse Bergen HF -Haukeland Hospital - Univ. Hosp, Bergen, Norway
PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 24
- Registration Number
- NCT05519540
- Locations
- 🇬🇧
Labcorp Clinical Research Unit Limited, Leeds, United Kingdom
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 166
- Registration Number
- NCT05386550
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Health System - UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States
🇨🇳Xiangya Hospital, Central South University, Changsha, China
🇨🇳Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China
A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Radiolabelled Xevinapant 100 μg (IV Solution)Drug: Radiolabelled Xevinapant 200 mg (Oral Solution)
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 12
- Registration Number
- NCT04962724
- Locations
- 🇬🇧
Labcorp Clinical Research Unit, Leeds, United Kingdom
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Radiation: Intensity Modulation Radiation Therapy (IMRT)Drug: Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 730
- Registration Number
- NCT04459715
- Locations
- 🇺🇸
Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇦Medical center of Yuriy Spizhenko, Soborna Vulytsia, Kyiv, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.